Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...